Short and Optimal Duration of Dual Antiplatelet Therapy Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1525 participants.

Also called NCT01659034

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,525 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01659034
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01659034. Allocation not applicable; no masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Short and Optimal Duration of Dual Antiplatelet Therapy Study
Acronym
STOPDAPT
Intervention (Drug)
Thienopyridine for 3 months
Lead sponsor
Takeshi Morimoto (class: other)

Record details

Record id
cardio:ct-nct01659034
Content hash
5a58c69f65d949bab68eb9b8c973584ac519e3ef6e749f9d6174ee00aab09f5b